

# ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE








	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa fever		University of Oxford	IAVI		
MERS	Uvax	IDT, Barinthus/University of Oxford			
Nipah		PHV	University of Oxford		
Rift Valley fever	UC Davis, Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
Chikungunya				IVI/Bharat	Valneva
COVID-19*					SK Bioscience, Biological E, Moderna, Clover, Novavax, AZ/Oxford, University of Hong Kong
Broadly protective Betacoronavirus	VIDO, Panacea/THSTI, IVI consortium, CPI/CalTech, Bharat/U Syd/ExcellGene, Intravacc	SK Bioscience			
Mpox			BioNTech		

(\* CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

# ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE




		Preclinical		Phase I	Phase II	Phase IIb/III & III	Registration
<p>Disease X</p>		Akagera	POP BIO	Centivax	Moderna		
		Chungbuk University	Gennova*	SK Bioscience			
		University of Queensland	Emervax				
		Sinergium	HMRI				
		University of Oxford	Imperial				
		Boost Biopharma	Nagasaki University				
		ACM Bio	VitriVax				
		IVI consortium	Abera Bioscience				
<p>Broadly protective Filovirus vaccines</p>		Adaptvac	Oxford/Leipzig/Moderna				
		Stanford					

(\* ) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

	DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
	Lassa fever	University of Oxford	Phase I	Viral Vector	Up to \$19 million†
		IAVI	Phase II	Viral Vector	Up to \$64.4 million
	MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million†
		IDT	Phase I	Viral vector	Up to \$36 million
		Uvax bio	Preclinical	Protein based	Up to \$2.6 million
	Nipah	University of Oxford	Phase II	Viral Vector	Up to \$19 million†
		PHV	Phase I	Viral vector	Up to \$43.6 million
	Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million
		Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
		University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
		Afrigen	Preclinical	mRNA	Up to \$6.2 million
	Chikungunya	IVI/Bharat	Phase I/II/III	Inactivated virus	Up to \$14.1 million
		Valneva	Registration	Live attenuated	Up to \$65.9 million
	COVID-19	SK Bioscience	Registration	Protein based	Up to \$210 million
		Biological E	Registration	Protein based	Up to \$14 million
		Moderna	Registration	Protein based	Up to \$1 million
		Clover	Registration	Protein based	Up to \$397.4 million
		University of Hong Kong	Registration	Live attenuated	Up to \$5.4 million
		AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
		Novavax	Registration	Protein based	Up to \$399 million
	Mpox	BioNTech	Phase II	mRNA	Up to \$91 million

(†) Includes Lassa, MERS and Nipah funding

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

	<b>Broadly protective Betacoronavirus</b>	IVI Consortium	Preclinical	mRNA	Up to \$23.9 million
		VIDO	Preclinical	Protein based	Up to \$22 million
		Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
		CPI/Caltech	Preclinical	Protein based	Up to \$30 million
		SK Bioscience	Phase I/II	Protein based	Up to \$50 million
		Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
		Intravacc	Preclinical	Protein based	Up to \$4.8 million
	<b>Disease X</b>	Abera Bioscience	Preclinical	Protein based	Up to \$1.5 million
		Akagera	Preclinical	mRNA	Up to \$1.5 million
		ACM Bio	Preclinical	mRNA	Up to \$2.9 million
		Boost Biopharma	Preclinical	Protein based	Up to \$5 million
		Centivax	Phase I	mRNA	Up to \$5.0 million
		Chungbuk National University	Preclinical	SaRNA	Up to \$0.9 million
		Emervax	Preclinical	CircRNA	Up to \$2.2 million
		Gennova	Preclinical	mRNA	Up to \$16.98 million##
		HMRI	Preclinical	CircRNA	Up to \$3.8 million
		Imperial College London	Preclinical	SaRNA	Up to \$8.4 million
		IVI, KDCA, ST Pharm, Seoul National University	Preclinical	mRNA	Up to \$16 million
		Moderna	Phase II	mRNA	Up to \$54.3 million
		Nagasaki University	Preclinical	mRNA	Up to \$5 million
		University of Oxford	Preclinical	Viral Vector	Up to \$80 million
		POP BIO	Preclinical	Protein based	Up to \$1.5 million
		University of Queensland	Preclinical	Protein based	Up to \$10.6 million
Sinergium	Preclinical	mRNA	Up to \$1 million		
SK Bioscience	Phase I/II	mRNA	Up to \$40 million		
VitriVax	Preclinical	Inactivated virus/Protein based	Up to \$5 million		
	<b>Broadly protective Filovirus vaccines</b>	AdaptVac	Preclinical	Virus-like particle	Up to \$12.4 million
		Stanford School of Medicine	Preclinical	Protein nanoparticle	Up to \$18 million
		University of Oxford, Leipzig Institute for Drug Discovery, Moderna	Preclinical	Viral vector and mRNA	Up to \$26.7 million

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.